Language:
English
日文
簡体中文
繁體中文
Help
Login
Back
Switch To:
Labeled
|
MARC Mode
|
ISBD
Melatonin, neuroprotective agents an...
~
Lopez-Munoz, Francisco.
Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /
Record Type:
Language materials, printed : Monograph/item
[NT 15000414]:
615.78
Title/Author:
Melatonin, neuroprotective agents and antidepressant therapy/ edited by Francisco Lopez-Munoz ... [et al.].
other author:
Lopez-Munoz, Francisco.
Published:
New Delhi : : Springer India :, 2016.
Description:
xxv, 921 p. : : ill., digital ;; 24 cm.
Contained By:
Springer eBooks
Subject:
Melatonin.
Subject:
Melatonin - Therapeutic use.
Subject:
Antidepressants.
Subject:
Medicine.
Subject:
Internal medicine.
Subject:
Neurology.
Subject:
Psychopharmacology.
Subject:
Medicine & Public Health.
Subject:
Internal Medicine.
ISBN:
9788132228035
ISBN:
9788132228011
[NT 15000229]:
This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.
Online resource:
http://dx.doi.org/10.1007/978-81-322-2803-5
Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /
Melatonin, neuroprotective agents and antidepressant therapy
[electronic resource] /edited by Francisco Lopez-Munoz ... [et al.]. - New Delhi :Springer India :2016. - xxv, 921 p. :ill., digital ;24 cm.
This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.
ISBN: 9788132228035
Standard No.: 10.1007/978-81-322-2803-5doiSubjects--Topical Terms:
558582
Melatonin.
LC Class. No.: RM297.M44
Dewey Class. No.: 615.78
Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /
LDR
:02491nam a2200301 a 4500
001
476738
003
DE-He213
005
20161117101939.0
006
m d
007
cr nn 008maaau
008
181208s2016 ii s 0 eng d
020
$a
9788132228035
$q
(electronic bk.)
020
$a
9788132228011
$q
(paper)
024
7
$a
10.1007/978-81-322-2803-5
$2
doi
035
$a
978-81-322-2803-5
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RM297.M44
072
7
$a
MJN
$2
bicssc
072
7
$a
MED056000
$2
bisacsh
082
0 4
$a
615.78
$2
23
090
$a
RM297.M44
$b
M517 2016
245
0 0
$a
Melatonin, neuroprotective agents and antidepressant therapy
$h
[electronic resource] /
$c
edited by Francisco Lopez-Munoz ... [et al.].
260
$a
New Delhi :
$b
Springer India :
$b
Imprint: Springer,
$c
2016.
300
$a
xxv, 921 p. :
$b
ill., digital ;
$c
24 cm.
520
$a
This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.
650
0
$a
Melatonin.
$3
558582
650
0
$a
Melatonin
$x
Therapeutic use.
$3
614997
650
0
$a
Antidepressants.
$3
487117
650
0
$a
Medicine.
$3
373206
650
0
$a
Internal medicine.
$3
206007
650
0
$a
Neurology.
$3
402687
650
0
$a
Psychopharmacology.
$3
372108
650
1 4
$a
Medicine & Public Health.
$3
463493
650
2 4
$a
Internal Medicine.
$3
341979
700
1
$a
Lopez-Munoz, Francisco.
$3
687742
710
2
$a
SpringerLink (Online service)
$3
463450
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-81-322-2803-5
950
$a
Medicine (Springer-11650)
based on 0 review(s)
Multimedia
Multimedia file
http://dx.doi.org/10.1007/978-81-322-2803-5
Reviews
Add a review
and share your thoughts with other readers
Export
pickup library
Processing
...
Change password
Login